NeuroSense Therapeutics Ltd (NRSN) Actualités

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically...

NeuroSense Announces First Quarter 2024 Business Update

NeuroSense Announces First Quarter 2024 Business Update PR Newswire CAMBRIDGE, Mass., May 2, 2024 CAMBRIDGE...

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical...

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at...

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 PR...

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement PR...

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative...

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update PR Newswire CAMBRIDGE...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial PR Newswire CAMBRIDGE...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule PR Newswire CAMBRIDGE, Mass., Feb. 7, 2024...